Inpatient and Outpatient Orderable

COVID-19 Antibody (Spike Domain) Build info

Synonyms

  • COVID-19 SPIKE DOMAIN ANTIBODY
  • COVIDSDAB
  • SARS-COV-2
  • LAB10447

Procedure Name

COVID-19 SPIKE DOMAIN ANTIBODY

Procedure Master Number

LAB10447

Procedure ID

111398

Clinical Info

Intended for semiquantitative detection of antibodies to SARS‑CoV‑2 spike protein. This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS‑CoV‑2, indicating recent/prior infection and/or COVID-19 vaccination.

Specimen Sources

 Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

 Blood

Container

Gold or Lithium Heparin (Mint-green) top tube

Collection Instructions

Specimen: 1.0 mL serum or plasma (0.5 mL min)
 

Specimen Volume

1.0 mL serum or plasma (0.5 mL min)

Transport Instructions

Refrigerated

Specimen Stability

14 days Room Temperature
14 Days Refrigerated
6 Months Frozen
 

Methodology

Days Performed

Sunday - Saturday
TAT: 2 Days

Performing Laboratory

Northwell Health Laboratories

CPT

86769

PDM

 2153036

Only Orderable at Locations:

 Orderable Everywhere

Results
Component Name Base Name Common Name External Name
COVID-19 SPIKE DOMAIN ANTIBODY COVID19SPAB COVID 19 SPIKE DOMAIN ANTIBODY COVID-19 Spike Domain Antibody
COVID-19 SPIKE DOMAIN ANTIBODY INTERPRETATION COV19ABINT COVID 19 SPIKE DOMAIN AB INTERPRETATION COVID-19 Spike Domain Antibody Interpretation

Result Interpretation

    Instrument (Assay)       Methodology   Anti-SARS-CoV-2 Antibody Interpretation
Roche 801 (Elecsys Anti-SARS-CoV-2 S) Electrochemiluminescence immunoassay < 0.80 U/mL : Negative for anti‑SARS‑CoV‑2‑S
≥ 0.80 U/mL : Positive for anti‑SARS‑CoV‑2‑S

The Roche Elecsys Anti‑SARS‑CoV‑2 S has been approved by the FDA for Emergency Use Authorization only. It has been validated to be accurate by Northwell Health Laboratories.

Positive results indicate that antibodies against SARS-CoV-2 were detected in your blood either from previous infection with SARS-CoV-2 virus and/or COVID-19 vaccination. Presence of antibodies to SARS‑CoV‑2 may not guarantee protection from SARS-CoV-2 reinfection.

Negative results do not preclude SARS‑CoV‑2 infection and should not be used as the sole basis for patient management decisions. A negative result can occur if the quantity of the anti‑SARS‑CoV‑2 antibodies is below the detection limits of the assay, or the antibodies that are detected are not present during the stage of disease in which a sample is collected. Follow-up testing with a molecular diagnostic tets should be considered to rule out infection in these individuals.

Forms
edit